Best approach if this is a viable company is to rely on earnings or money from a partner to fund any further R&D and stop diluting. Issuing more shares to let HEP Investments reduce their cost basis also is not a solution. And get rid of the director of research and others who have failed at their jobs. Ridiculous they continued to spend without committed funds from a partner or a reliable revenue stream. The treasury management has been a disaster, and the board has let it happen. The market is pricing Zivo at a million bucks while they have spent $100 million mostly on research and administrative expenses. Imagine if they spent just half of that on algae production and marketing to actually sell something and generate earnings.